MX2022003150A - Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2). - Google Patents

Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2).

Info

Publication number
MX2022003150A
MX2022003150A MX2022003150A MX2022003150A MX2022003150A MX 2022003150 A MX2022003150 A MX 2022003150A MX 2022003150 A MX2022003150 A MX 2022003150A MX 2022003150 A MX2022003150 A MX 2022003150A MX 2022003150 A MX2022003150 A MX 2022003150A
Authority
MX
Mexico
Prior art keywords
dosage forms
tyk2
inhibitors
tyrosine kinase
methyl
Prior art date
Application number
MX2022003150A
Other languages
English (en)
Spanish (es)
Inventor
Ian Yates
Corey Bloom
Sherif Ibrahim Farag Badawy
Jonathan R Brown
Candice Y Choi
Christoph Gesenberg
Vivienne Gray
John Wynne Jones
Umesh Kestur
Balvinder S Vig
Xiaotian S Yin
Christopher A Zordan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022003150A publication Critical patent/MX2022003150A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2022003150A 2019-09-18 2020-09-18 Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2). MX2022003150A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962902218P 2019-09-18 2019-09-18
PCT/US2020/051342 WO2021055652A1 (en) 2019-09-18 2020-09-18 Dosage forms for tyk2 inhibitors

Publications (1)

Publication Number Publication Date
MX2022003150A true MX2022003150A (es) 2022-04-06

Family

ID=72670853

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2022003150A MX2022003150A (es) 2019-09-18 2020-09-18 Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2).
MX2022003146A MX2022003146A (es) 2019-09-18 2020-09-18 Formas de dosificacion de liberacion prolongada para los inhibidores de tirosina cinasa 2 (tyk2).
MX2025014307A MX2025014307A (es) 2019-09-18 2022-03-15 Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2)
MX2025014308A MX2025014308A (es) 2019-09-18 2022-03-15 Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2)

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2022003146A MX2022003146A (es) 2019-09-18 2020-09-18 Formas de dosificacion de liberacion prolongada para los inhibidores de tirosina cinasa 2 (tyk2).
MX2025014307A MX2025014307A (es) 2019-09-18 2022-03-15 Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2)
MX2025014308A MX2025014308A (es) 2019-09-18 2022-03-15 Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2)

Country Status (20)

Country Link
US (4) US12521390B2 (https=)
EP (3) EP4031109B1 (https=)
JP (3) JP7812785B2 (https=)
KR (2) KR20220066310A (https=)
CN (8) CN114727949A (https=)
AU (1) AU2020348783B2 (https=)
BR (2) BR112022004216A2 (https=)
CA (2) CA3151137A1 (https=)
DK (1) DK4031110T3 (https=)
ES (1) ES3060149T3 (https=)
FI (1) FI4031110T3 (https=)
HR (1) HRP20260058T1 (https=)
IL (2) IL291452A (https=)
LT (1) LT4031110T (https=)
MX (4) MX2022003150A (https=)
PL (1) PL4031110T3 (https=)
PT (1) PT4031110T (https=)
RS (1) RS67803B1 (https=)
SI (1) SI4031110T1 (https=)
WO (2) WO2021055651A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7812785B2 (ja) * 2019-09-18 2026-02-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の剤形
IL301389A (en) * 2020-09-18 2023-05-01 Bristol Myers Squibb Co Dosage forms for tyk2 inhibitors comprising swellable cores
CA3208361A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
EP4294806A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
EP4404930A1 (en) 2021-09-23 2024-07-31 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
JP2024539703A (ja) * 2021-10-28 2024-10-29 ブリストル－マイヤーズ スクイブ カンパニー デュークラバシチニブの局所製剤
WO2023181075A1 (en) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof
AR128868A1 (es) * 2022-03-25 2024-06-19 Nimbus Lakshmi Inc Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
WO2024176263A1 (en) * 2023-02-22 2024-08-29 Cipla Limited Deucravacitinib amorphous solid dispersions and polymorphs thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
ATE400251T1 (de) * 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
ATE404178T1 (de) 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
EP1967185A1 (en) 1999-12-23 2008-09-10 Pfizer Products Inc. Hydrogel-driven drug dosage form
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
CN1625397A (zh) 2002-02-01 2005-06-08 辉瑞产品公司 胆固醇酯转移蛋白抑制剂的控制释放药物剂型
US20090011018A1 (en) 2006-12-28 2009-01-08 Astellas Pharma Inc., Sustained release formulation for tacrolimus
CN101152158B (zh) 2007-08-21 2010-05-26 浙江大学 一种药物的双层芯渗透泵片的制备方法
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
EP2734190A1 (en) 2011-07-21 2014-05-28 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
JP6404217B2 (ja) * 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
EP2895150A1 (en) 2012-09-11 2015-07-22 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
JP2015531365A (ja) * 2012-09-28 2015-11-02 オンコエシックス エスエー チエノトリアゾロジアゼピン化合物を含む医薬製剤
LT3495358T (lt) * 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
US9895308B2 (en) 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
JP7113023B2 (ja) 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
KR102848769B1 (ko) 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
JP7812785B2 (ja) * 2019-09-18 2026-02-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の剤形
IL301389A (en) * 2020-09-18 2023-05-01 Bristol Myers Squibb Co Dosage forms for tyk2 inhibitors comprising swellable cores

Also Published As

Publication number Publication date
CN119424435A (zh) 2025-02-14
LT4031110T (lt) 2026-02-25
WO2021055652A1 (en) 2021-03-25
US20260083733A1 (en) 2026-03-26
KR20220066310A (ko) 2022-05-24
US20230255964A1 (en) 2023-08-17
BR112022004550A2 (pt) 2022-05-31
MX2025014307A (es) 2026-01-07
EP4706778A2 (en) 2026-03-11
CN119424434A (zh) 2025-02-14
US12521390B2 (en) 2026-01-13
AU2020348783B2 (en) 2026-04-16
CN119700773A (zh) 2025-03-28
FI4031110T3 (fi) 2026-03-10
CN119700772A (zh) 2025-03-28
JP2022548687A (ja) 2022-11-21
JP7719770B2 (ja) 2025-08-06
MX2022003146A (es) 2022-04-06
US20220331315A1 (en) 2022-10-20
PL4031110T3 (pl) 2026-03-30
DK4031110T3 (da) 2026-03-23
AU2020349524A1 (en) 2022-03-31
IL291453A (en) 2022-05-01
US20260083734A1 (en) 2026-03-26
CN114727948A (zh) 2022-07-08
AU2020348783A1 (en) 2022-03-31
HRP20260058T1 (hr) 2026-02-27
CA3151369A1 (en) 2021-03-25
JP7812785B2 (ja) 2026-02-10
SI4031110T1 (sl) 2026-03-31
EP4031110A1 (en) 2022-07-27
JP2025163082A (ja) 2025-10-28
EP4031109A1 (en) 2022-07-27
CN114727949A (zh) 2022-07-08
RS67803B1 (sr) 2026-03-31
BR112022004216A2 (pt) 2022-05-31
CN119424433A (zh) 2025-02-14
JP2022548688A (ja) 2022-11-21
EP4031110B1 (en) 2025-12-24
WO2021055651A1 (en) 2021-03-25
ES3060149T3 (en) 2026-03-25
CA3151137A1 (en) 2021-03-25
EP4031109C0 (en) 2026-02-18
IL291452A (en) 2022-05-01
PT4031110T (pt) 2026-02-03
CN119745885A (zh) 2025-04-04
MX2025014308A (es) 2026-01-07
KR20220066105A (ko) 2022-05-23
EP4031109B1 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
MX2022003150A (es) Formas de dosificacion para los inhibidores de tirosina cinasa 2 (tyk2).
DOP2022000096A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
MX2017011270A (es) Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton.
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
ECSP18083443A (es) Formulaciones líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil) -pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
MX2017016217A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
MX2016010754A (es) Sales y forma solida de un inhibidor btk.
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
ES3057783T3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
UY30328A1 (es) Derivados de 2-piridona, procesos de preparacion, composiciones conteniéndolos y aplicaciones.
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CL2011000195A1 (es) Compuestos derivados de 5-alquinil-pirimidina, inhibidores de quinasas; composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer.
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
MX2024010568A (es) Compuestos terapeuticos, formulaciones y uso de estos.
MX2007007610A (es) Regimen de cladribina para tratar esclerosis multiple.
MX386521B (es) Composiciones farmaceuticas que contienen un relajante muscular y un antiinflamatorio no esteroideo (aine).
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
AR126542A1 (es) Formas sólidas y formulaciones de un inhibidor de quinasas tam y c-met
GT200600242A (es) Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil)ftalazin-1-ilo] no micronizado, y sus sales